$NUVB GSK/Nuvalent zidesamtinib - strong first line data. 15% CR. Roughly a year from market.
Dr. @alexdrilon at #WCLC26 presents 1L cohort of ARROS-1 trial of zidesamtinib in pts with ROS1 NSCLC. What a waterfall plot. RR 94% with 15% CR. mPFS not reached, PFS at 6m was 96% and at 12m was 90%. Intracranial RR 100%. In 78 pts who did not have brain metastases at baseline, no CNS events occurred to date. These are fantastic outcomes.
$NUVB Ibtrozi competition in 2nd line approved early. Jideytro first line data submission expected in 2026 $NUVL $GSK. gsk.com/en-gb/media/press-re…
1
711
$UNCY the second CRL appears to confirm that the company resubmitted without the third party having addressed the deficiencies. $UNCY "believed" progress had been made. Incredible incompetence, if true download.open.fda.gov/crl/CR…
$UNCY received a second CRL for the exact same manufacturing issue and basically admits they resubmitted because they “believed” the third-party vendor had made enough progress.
What a joke!
1
7
2,201
$REPL This thread 👍 - but hey, "innovation died today" 🤷♂️🤯
Replying to @MaverickNY
Just how bad is it? It's pretty bad in my book. The FDA letter documents a pattern going well beyond weak science into what seems like a deliberate strategy to ignore regulators and hope for the best.
$REPL What a pitiful and ridiculous press release ir.replimune.com/news-releas…
2
13
2,201
Dude, they told them >5 years ago, long before you and everyone elese started ranting about the "new" "bad" FDA"
"Or is it the FDA that's lost all credibility. After a year of politically aligning staff, it will take a long time repairing the agency." $REPL
$repl all the docs that wrote the letter last year for why RP1 should be approved and attensed the subsequent FDA meeting obviously have no credibility.
Or is it the FDA that's lost all credibility. After a year of politically aligning staff, it will take a long time repairing the agency.
$REPL A lot of biotwitter "influencers" looking very foolish today- wild CRL download.open.fda.gov/crl/CR…
5
709
$ALMS Alumis’ Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis | Alumis Inc. investors.alumis.com/news-re…
1
785
$VIR Astellas only taking rights for PSMA program. Everything else is unencumbered. 👀 investors.vir.bio/news/news-…

















